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Dear Editors,
We would like to thank Drs. Fusco, Bedogni, Addeo, and
Campisi [1] and Drs. Boissieu and Trenque [2] for their inter-
est and review of our study report [3].
Our long-term safety study [3] was based on denosumab
exposure (Q4W, 120 mg SC dosing) and focused on the iden-
tification of any new safety signals as well as known adverse
events such as osteonecrosis of the jaw (ONJ) in patients with
either advanced breast or prostate cancer. The data were taken
from the primary skeletal-related events (SRE) trials [4, 5] and
their respective open-label extension (OLE) phases (up to 2
additional years). Adverse events were monitored and poten-
tial ONJ events were adjudicated by an independent commit-
tee of oral surgeons and dentists [4, 5]. Patient-year adjusted
event rates of adjudicated positive ONJ were summarized.
In the first Letter To The Editor by Fusco et al., the authors
comments are as follows:
1) Provide clarity of median denosumab exposure.
As originally described in Stopeck et al. [3], the median
denosumab exposure (range) for the primary and the OLE
phases combined was 19.1 months (0.1–59.8 months)
for the breast cancer population (n = 1019) and 12.0
(0.1–67.2 months) for the prostate cancer population
(n = 942). There was some confusion by Fusco et al. on the
length of time for the median denosumab exposure of the OLE
phase only, which we originally reported in Stopeck et al. [3]
as 17.6 months (0–23.7 months) for the breast cancer popula-
tion (n = 318) and 12.0 months (0.1–23.3 months) for the
prostate cancer population (n = 147).
2) Clarify why the ONJ rates reported in the OLE safety
manuscript are higher than what was originally reported
for the primary analyses of the primary SRE studies.
The higher reported ONJ rates in the OLE safety manu-
script [3] are due to the higher cumulative exposure of the
respective antiresorptive treatment. For example, the
denosumab/denosumab patient group (n = 318 for breast and
n = 147 for prostate cancer) in the OLE analysis was exposed
to denosumab during the blinded treatment phase until the
completion of the blinded treatment phase, with additional
denosumab exposure in the OLE phase for up to 2 years.
Therefore, the median cumulative denosumab exposure was
43.0 months for breast cancer (n = 318) and 36.9 months for
prostate cancer (n = 147) groups. The resulting ONJ rates are
higher for these denosumab/denosumab patients in the OLE
phase of these two studies, which are expected and consistent
with the observation that ONJ risk increases with longer ex-
posure of denosumab as documented in the XGEVA® pre-
scribing information [6]. The patient-year adjusted incidence
of confirmed ONJ was 1.1% during the first year of
denosumab treatment, 3.7% in the second year, and 4.6%
per year thereafter. The ONJ rates reported in Table 3 of the
OLE safety manuscript are the rates for the OLE phase only.
For both primary SRE studies, patients who had positively
adjudicated ONJ during the blinded treatment phase were
not enrolled in the OLE phase.
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3) What were the guidelines used for determining positively
adjudicated ONJ at the time of analysis?
The methodology used to determine which cases of ONJ
were sent for adjudication was based on a search using clinical
terms from the MEDRA guidelines at the time of the study. In
our study, the breast cancer patients/denosumab arm had 119
patients with potential ONJ and 48 patients that were positive-
ly adjudicated. For the zoledronic acid arm, 93 patients were
identified with potential ONJ and 35 patients were positively
adjudicated. For the prostate cancer patients/denosumab arm,
75 patients were identified with potential ONJ and 36 patients
were positively adjudicated. For the zoledronic arm, 54 pa-
tients were identified with potential ONJ and 21 were posi-
tively adjudicated. However, as mentioned by Fusco et al.,
AAOMs [7] updated and broadened the definition of ONJ in
2014, which was after the collection of ONJ data from our
primary and OLE phases of the study.
4) Suggestion for an analysis of the OLE subset only (Fusco
et al.) as compared to the analysis of the combined pri-
mary and OLE subsets as presented in Stopeck et al. [3].
The primary goal of the Stopeck et al. manuscript [3] was
to provide a comprehensive safety summary for both the
breast and prostate cancer patient populations based on the
primary SRE studies and OLE data. The specific analysis
suggested by Fusco et al. would look at a narrow subset of
OLE patients who have not experienced ONJ over a certain
period of exposure and their risk in further exposure to
denosumab. Although interesting, this was not the aim of the
manuscript and has inherent limitations which could obscure
and possible mislead clinical interpretation.
In the second Letter To The Editor by Boissieu et al., the
authors comments are as follows:
1) In regards to the reported number of positively adjudicat-
ed ONJ patients, clarify the differences between what was
reported in the primary SRE trials for breast [4] and
prostate [5] cancer patients and what was reported in
the current, Stopeck et al. safety manuscript [3].
In both the primary SRE trial manuscripts [4, 5], the
number of positively adjudicated ONJ cases was report-
ed up to the primary analysis (PA) cutoff date of 06-
Mar-2009 for the breast cancer and 30-Oct-2009 for the
prostate cancer trials. For the Stopeck et al. safety
manuscript [3], the total number of positively adjudicat-
ed ONJ cases (breast and prostate cancer patients) dur-
ing the blinded treatment phase refers to the data up to
the end-of-blinded treatment phase (DBE) cutoff date
(20-Jul-2009 for the breast and 26-Feb-10 for the pros-
tate cancer trial), which occurred approximately
4 months after the PA cutoff date. The DBE time period
is where the additional, positively adjudicated ONJ
cases were accrued for both the denosumab and zole-
dronic arms when compared to the primary SRE trials.
In the breast cancer trial, the numbers of positively ad-
judicated ONJ cases in denosumab arm vs zoledronic
acid arm were 20 (2.0%) vs 14 (1.4%) by PA cutoff
and increased to 26 (2.5%) vs 18 (1.8%) by DBE cut-
off. In the prostate cancer trial, the numbers were 22
(2.3%) and 12 (1.3%) by PA cutoff and increase to 23
(2.4%) and 13 (1.4%) by DBE cutoff. In both trials,
ONJ rates were not statistically higher for denosumab
compared with zoledronic acid based on the data up to
DBE. This conclusion is consistent with results based
on PA data as reported in the original PA for the breast
and prostate cancer populations [4, 5].
We agree that patients on antiresorptive therapies should be
diligently monitored for oral complication, encouraged to
practice good oral hygiene, and referred to a trained dental
health professional for dental symptoms.
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